Physician profile
William Mcglathery
NPI 1659329555
$3,042.87
in general payments reported to CMS, 2019-2025
20 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $201 · 2021: $465 · 2022: $437 · 2023: $439 · 2024: $351 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $751.07 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Abbvie INC. | $562.99 | 2022-2025 | |
| Allergan, INC. | $521.50 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $188.26 | 2023-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Novartis Pharmaceuticals Corporation | $139.94 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $109.37 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $86.78 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $85.98 | 2021-2025 | |
| Biotissue Holdings INC. | $83.15 | 2019-2022 | |
| Thea Pharma INC. | $83.12 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $81.29 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.88 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $56.43 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $53.31 | 2019-2021 | |
| Shire North American Group INC | $40.84 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $37.90 | 2021-2022 | |
| Amgen INC. | $34.90 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $21.04 | 2023 | Tepezza |
| Rxsight INC | $20.69 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Tearlab Corp | $16.43 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcglathery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.